ProCE Banner Activity

Phase II Study: Inotuzumab Ozogamicin + Low-Intensity Chemo ± Blinatumomab in Newly Diagnosed Older Patients With Ph- ALL

Slideset Download
Conference Coverage
Early results show addition of blinatumomab to inotuzumab ozogamicin plus mini-HCVD efficacious in older patients with newly diagnosed Ph- ALL.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology